MA51287A - Analogues d'incrétine et leurs utilisations - Google Patents
Analogues d'incrétine et leurs utilisationsInfo
- Publication number
- MA51287A MA51287A MA051287A MA51287A MA51287A MA 51287 A MA51287 A MA 51287A MA 051287 A MA051287 A MA 051287A MA 51287 A MA51287 A MA 51287A MA 51287 A MA51287 A MA 51287A
- Authority
- MA
- Morocco
- Prior art keywords
- incretin
- analogues
- incretin analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608644P | 2017-12-21 | 2017-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51287A true MA51287A (fr) | 2021-03-31 |
Family
ID=65003515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051287A MA51287A (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11834486B2 (fr) |
| EP (1) | EP3727425A1 (fr) |
| JP (2) | JP6987993B2 (fr) |
| KR (1) | KR102440323B1 (fr) |
| CN (1) | CN111511387A (fr) |
| AR (1) | AR113487A1 (fr) |
| AU (1) | AU2018388895B2 (fr) |
| BR (1) | BR112020010410A2 (fr) |
| CA (1) | CA3084004C (fr) |
| CL (1) | CL2020001636A1 (fr) |
| CO (1) | CO2020006253A2 (fr) |
| CR (1) | CR20200256A (fr) |
| DO (1) | DOP2020000124A (fr) |
| EA (1) | EA202091284A1 (fr) |
| EC (1) | ECSP20032306A (fr) |
| IL (1) | IL275469A (fr) |
| JO (1) | JOP20200136A1 (fr) |
| MA (1) | MA51287A (fr) |
| MX (1) | MX2020006547A (fr) |
| PH (1) | PH12020551024A1 (fr) |
| SG (1) | SG11202004359YA (fr) |
| TW (2) | TWI810937B (fr) |
| UA (1) | UA127589C2 (fr) |
| WO (1) | WO2019125929A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| SG11202100128UA (en) * | 2018-07-23 | 2021-02-25 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| TWI764209B (zh) | 2019-08-01 | 2022-05-11 | 美商美國禮來大藥廠 | Gipr促效劑化合物 |
| WO2021034815A1 (fr) | 2019-08-19 | 2021-02-25 | Eli Lilly And Company | Procédés de fabrication d'analogues d'incrétine |
| TWI795698B (zh) * | 2019-12-18 | 2023-03-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| MX2022009149A (es) * | 2020-01-23 | 2022-12-15 | Lilly Co Eli | Compuestos coagonistas de gip/glp1. |
| WO2022035271A1 (fr) * | 2020-08-14 | 2022-02-17 | 한미약품 주식회사 | Composition pharmaceutique comprenant un conjugué persistant de triple activateur utilisé comme principe actif |
| JP2023550594A (ja) | 2020-10-30 | 2023-12-04 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬 |
| AR125086A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Composiciones que contienen análogos de incretina y usos de estas |
| AU2022280225A1 (en) | 2021-05-26 | 2024-01-04 | The United Bio-Technology (Hengqin) Co., Ltd. | Multi-agonist and use thereof |
| CN115572326A (zh) * | 2021-06-21 | 2023-01-06 | 广东东阳光药业有限公司 | Glp-1、gcg和gip受体的三重激动剂 |
| EP4358994A1 (fr) | 2021-06-23 | 2024-05-01 | Eli Lilly and Company | Analogue d'incrétine utilisé dans la gestion du poids et le contrôle de la glycémie |
| WO2023088140A1 (fr) * | 2021-11-19 | 2023-05-25 | 南京明德新药研发有限公司 | Peptide agrafé et son utilisation |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| WO2024067662A1 (fr) * | 2022-09-28 | 2024-04-04 | 广东东阳光药业股份有限公司 | Agoniste du récepteur triple glp-1/gcg/gip et son utilisation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1013588A2 (pt) | 2009-03-27 | 2016-04-19 | Glaxo Group Ltd | composição |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| US10093713B2 (en) * | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| CA2929107C (fr) | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Composes agonistes triples glucagon-glp-1-gip |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
| AR104932A1 (es) | 2015-06-22 | 2017-08-23 | Lilly Co Eli | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| EP3217027A1 (fr) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Élement de revetement large destine a entourer une tige d'ancrage |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2018
- 2018-12-05 TW TW111118551A patent/TWI810937B/zh active
- 2018-12-05 TW TW107143623A patent/TWI767095B/zh active
- 2018-12-06 AR ARP180103573A patent/AR113487A1/es unknown
- 2018-12-14 US US16/769,015 patent/US11834486B2/en active Active
- 2018-12-14 UA UAA202002893A patent/UA127589C2/uk unknown
- 2018-12-14 BR BR112020010410-8A patent/BR112020010410A2/pt unknown
- 2018-12-14 CN CN201880082714.8A patent/CN111511387A/zh active Pending
- 2018-12-14 JP JP2020532952A patent/JP6987993B2/ja active Active
- 2018-12-14 WO PCT/US2018/065605 patent/WO2019125929A1/fr unknown
- 2018-12-14 EP EP18830614.6A patent/EP3727425A1/fr active Pending
- 2018-12-14 AU AU2018388895A patent/AU2018388895B2/en active Active
- 2018-12-14 SG SG11202004359YA patent/SG11202004359YA/en unknown
- 2018-12-14 KR KR1020207017385A patent/KR102440323B1/ko active IP Right Grant
- 2018-12-14 MX MX2020006547A patent/MX2020006547A/es unknown
- 2018-12-14 CR CR20200256A patent/CR20200256A/es unknown
- 2018-12-14 EA EA202091284A patent/EA202091284A1/ru unknown
- 2018-12-14 MA MA051287A patent/MA51287A/fr unknown
- 2018-12-14 JO JOP/2020/0136A patent/JOP20200136A1/ar unknown
- 2018-12-14 CA CA3084004A patent/CA3084004C/fr active Active
-
2020
- 2020-05-22 CO CONC2020/0006253A patent/CO2020006253A2/es unknown
- 2020-06-17 PH PH12020551024A patent/PH12020551024A1/en unknown
- 2020-06-17 IL IL275469A patent/IL275469A/en unknown
- 2020-06-17 DO DO2020000124A patent/DOP2020000124A/es unknown
- 2020-06-17 CL CL2020001636A patent/CL2020001636A1/es unknown
- 2020-06-19 EC ECSENADI202032306A patent/ECSP20032306A/es unknown
-
2021
- 2021-12-01 JP JP2021195036A patent/JP2022043082A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091284A1 (ru) | 2020-09-08 |
| CO2020006253A2 (es) | 2020-05-29 |
| EP3727425A1 (fr) | 2020-10-28 |
| KR102440323B1 (ko) | 2022-09-05 |
| AR113487A1 (es) | 2020-05-06 |
| JP2021506825A (ja) | 2021-02-22 |
| AU2018388895B2 (en) | 2020-12-24 |
| US20210221865A1 (en) | 2021-07-22 |
| BR112020010410A2 (pt) | 2020-11-24 |
| TW202233227A (zh) | 2022-09-01 |
| US11834486B2 (en) | 2023-12-05 |
| JOP20200136A1 (ar) | 2022-10-30 |
| CA3084004C (fr) | 2023-06-20 |
| TW201938187A (zh) | 2019-10-01 |
| JP2022043082A (ja) | 2022-03-15 |
| PH12020551024A1 (en) | 2021-05-31 |
| JP6987993B2 (ja) | 2022-01-05 |
| DOP2020000124A (es) | 2020-08-31 |
| WO2019125929A1 (fr) | 2019-06-27 |
| TWI810937B (zh) | 2023-08-01 |
| MX2020006547A (es) | 2020-12-09 |
| CA3084004A1 (fr) | 2019-06-27 |
| UA127589C2 (uk) | 2023-10-25 |
| CN111511387A (zh) | 2020-08-07 |
| CL2020001636A1 (es) | 2020-10-16 |
| KR20200088418A (ko) | 2020-07-22 |
| AU2018388895A1 (en) | 2020-06-04 |
| IL275469A (en) | 2020-08-31 |
| ECSP20032306A (es) | 2020-07-31 |
| SG11202004359YA (en) | 2020-06-29 |
| CR20200256A (es) | 2020-07-12 |
| TWI767095B (zh) | 2022-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA50502A (fr) | Adénovirus et utilisations associées | |
| MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
| MA50265A (fr) | Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations | |
| MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| MA53660A (fr) | Analogues de stérol et leurs utilisations | |
| MA44665A (fr) | Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques |